How is primary central nervous system lymphoma (PCNSL) prevented?

Updated: Jul 06, 2021
  • Author: Caroline T Goldin, MD; Chief Editor: Stephen A Berman, MD, PhD, MBA  more...
  • Print


Because the reasons for the development of PCNSL in immunocompetent patients are unknown, whether deterrent or preventive maneuvers can be undertaken also is unknown.

Patients receiving immunosuppressive therapy after organ transplantation should receive the smallest effective doses compatible with the viability of the transplant. Corticosteroid-sparing therapy is advised, and lowering of the intensity of immunosuppression, if feasible, is advised for transplant recipients who develop PCNSL.

Patients with AIDS who have low CD4+ counts are at the greatest risk for PCNSL. The extent to which highly effective antiretroviral therapy will affect the incidence and prognosis of PCNSL in AIDS is not yet known.

Did this answer your question?
Additional feedback? (Optional)
Thank you for your feedback!